Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable Huntington's disease patients—A randomized phase 2 clinical trial

Authors

Michael J Brownstein, Azevan Pharmaceuticals, Inc.
Joel S Perlmutter, Washington University School of Medicine in St. Louis
Elaine Most, Washington University School of Medicine in St. Louis
et al

Journal

Journal of Clinical Medicine

Publication Date

2020

Volume

9

Issue

11

First Page

3682

Document Type

Open Access Publication

DOI

10.3390/jcm9113682

Rights and Permissions

Brownstein MJ, Simon NG, Long JD, et al. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020;9(11):3682. Published 2020 Nov 16. doi:10.3390/jcm9113682

Recommended Citation

Brownstein, Michael J; Perlmutter, Joel S; Most, Elaine; and et al, "Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable Huntington's disease patients—A randomized phase 2 clinical trial." Journal of Clinical Medicine. 9, 11. 3682 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9969